Filing Flows › Intellia Therapeutics (NTLA) › Q3 2026
Intellia Therapeutics (NTLA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Intellia Therapeutics (NTLA) reported revenue of $7.2M for the third quarter 2026 (Q3 2026), -48% from a year earlier and -6% from the quarter before.
Intellia Therapeutics, Q3 2026: revenue $7.2M (-48% year over year), net loss $127M, operating cash flow −$85.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.2M | -6% | -48% |
| Operating profit | −$122M | — | — |
| Net earnings | −$127M | — | — |
| Operating cash flow | −$85.4M | — | — |
What changed
Revenue was $7.2M in Q3 2026, down 48% year over year and down 6% from the previous quarter.
Operating costs exceeded revenue by $122.3M, an operating margin of -1707.7%. Total costs grew 3% against a revenue fall of 48%. The fastest-growing cost line was General & admin (+51%). The quarter ended with a net loss of $127.5M, wider than the previous quarter's $106.6M loss.
Operating cash flow was −$85.4M. Non-cash charges added back $1.9M of depreciation and amortization and $14.4M of share-based compensation. Working capital and other items added $25.8M. Capital expenditures of $888K exceeded it, leaving free cash flow of −$86.3M.
Questions
What was Intellia Therapeutics' revenue in the third quarter 2026?
Intellia Therapeutics (NTLA) reported revenue of $7.2M for the third quarter 2026 (Q3 2026), -48% from a year earlier and -6% from the quarter before.